Efficacy and Safety of the Dopaminergic Stabilizer Pridopidine (ACR16) in Patients With Huntington's Disease-Reference-Cited by-同舟云学术

Efficacy and Safety of the Dopaminergic Stabilizer Pridopidine (ACR16) in Patients With Huntington's Disease

Published:2010-09 Issue:5 Volume:33 Page:260-264
ISSN:0362-5664
Container-title:Clinical Neuropharmacology
language:en
Short-container-title:

Author:

Lundin Anders,Dietrichs Espen,Haghighi Sara,Göller Marie-Louise,Heiberg Arvid,Loutfi Ghada,Widner Håkan,Wiktorin Klas,Wiklund Leif,Svenningsson Anders,Sonesson Clas,Waters Nicholas,Waters Susanna,Tedroff Joakim

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Clinical Neurology,Pharmacology

Reference18 articles.

1. Recent advances in Huntington's disease.;Gutekunst;Curr Opin Neurol,2000

2. Huntington's disease.;Walker;Lancet,2007

3. Behavioral changes in Huntington's disease.;Craufurd;Neuropsychiatry Neuropsychol Behav Neurol,2001

4. Pharmacological management of Huntington's disease: an evidence-based review.;Bonelli;Curr Pharm Des,2006

5. The dopamine stabilizers (S)-()-(3-methanesulfonyl-phenyl)-1-propyl-piperidine ()-OSU6162 and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat.;Natesan;J Pharmacol Exp Ther,2006

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Depression in Huntington’s Disease: A Systematic Review;The Journal of Neuropsychiatry and Clinical Neurosciences;2024-03-26

2. Gut microbiota dysbiosis and Huntington's disease: Exploring the gut-brain axis and novel microbiota-based interventions;Life Sciences;2023-09

3. From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington’s Disease Research;International Journal of Molecular Sciences;2023-08-21

4. Fountain of youth—Targeting autophagy in aging;Frontiers in Aging Neuroscience;2023-03-29

5. Current and Possible Future Therapeutic Options for Huntington’s Disease;Journal of Central Nervous System Disease;2022-01